ReviewHuman cell2020
Clinical relevance of tumor microenvironment: immune cells, vessels, and mouse models.
Review in Human cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- ASO Author Reflections: Clinical Relevance of Aurora Kinase A (AURKA) Gene Expression in ER+/HER2- Breast Cancer.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Neuronal Signature Enrichment Distinguishes a Type of Gastric Cancer with Poor Prognosis.Annals of surgical oncology · 2026Article
- Neuron-Associated Transcriptional Enrichment Is Associated with Distinct Biological States and Predicts Poor Prognosis in Gastric Cancer.Annals of surgical oncology · 2026Article
- Macroscopic polarimetric discrimination and quantification of antiangiogenic effect of AGRO aptamer and GK1 peptide in a preclinical melanoma model.Scientific reports · 2026Article
- CD73 is associated with glycolysis related metabolic programs and CD8Frontiers in immunology · 2026Article
- Natural carrier systems in cancer vaccines and immunotherapy.Human vaccines & immunotherapeutics · 2025Review
- Advances and Challenges in Drug Screening for Cancer Therapy: A Comprehensive Review.Bioengineering (Basel, Switzerland) · 2025Review
- Bone morphogenetic proteins (BMPs) at the forefront of ocular diseases and therapeutics.Eye and vision (London, England) · 2025Review
- Disparate Roles of Cell-Cell Contact and Cytokine Secretion in an In Vitro Model of the Seminoma Microenvironment.International journal of molecular sciences · 2025Article
- A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine.Current cancer drug targets · 2025Review
- Identification of tumor associated neutrophils-related genes in triple-negative breast cancer for predicting prognosis and therapeutic response through integrated single-cell analysis.Frontiers in immunology · 2025Article
- Decoding the immune microenvironment: unveiling CD8 + T cell-related biomarkers and developing a prognostic signature for personalized glioma treatment.Cancer cell international · 2024Article
- Prognostic Significance of CD11b-, CD8-, and CD163-Positive Tumor-Infiltrating Immune Cells in Distal Bile Duct Cancer.Journal of personalized medicine · 2024Article
- Pumilio RNA binding family member 1 deficiency activates anti-tumor immunity in hepatocellular carcinoma via restraining M2 macrophage polarization.Cell cycle (Georgetown, Tex.) · 2024Article
- The Metformin Immunoregulatory Actions in Tumor Suppression and Normal Tissues Protection.Current medicinal chemistry · 2024Review
- Extracellular vesicles and cancer stem cells: a deadly duo in tumor progression.Oncology reviews · 2024Review
- Systematic Multiomic Analysis ofInternational journal of molecular sciences · 2023Article
- Low CDKN1B Expression Associated with Reduced CD8+ T Lymphocytes Predicts Poor Outcome in Breast Cancer in a Machine Learning Analysis.Journal of personalized medicine · 2023Article
- Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment.Journal of cancer research and clinical oncology · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The tumor microenvironment (TME) plays a crucial role in tumor progression, therapeutic response, and patient outcomes. TME includes immune cells, blood and lymphatic vessels, and so on. There are anti-cancer and pro-cancer immune cells. In general, infiltration of anti-cancer immune cells, such as cytotoxic T cells (CTLs), is associated with a favorable patient prognosis. In contrast, infiltration of pro-cancer immune cells, such as regulatory T cells (Tregs), tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), is associated with a worse prognosis. However, some immune cells, which play an ambivalent role in cancer immunity, have demonstrated contradictory impacts on patient prognosis. Blood and lymphatic vessels play crucial roles in TME not only as delivery and draining systems of fluid and molecules, but also allowing cancer cells access to systematic circulation to metastasize. Angiogenesis promotes cancer aggressiveness and is associated with a worse prognosis. Its targeted therapy shows a benefit in some cancers, however, because the target can vary by caner type, a benefit of anti-angiogenesis therapy is limited in the current standard of care. Lymphangiogenesis plays a role in lymph node metastasis, thus, it is associated with a poor prognosis in some cancers. To study TME, the mouse model is one of the most commonly used tools. The choice of appropriate mouse model depends on the hypothesis being tested and the scientific question being asked. Here, we review recent studies that investigated the clinical relevance of TME components and introduce mouse models to study TME.
Indexed as
Identifiers
32507979What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.